Big beat?This has been a strong quarter, quantitatively and qualitatively: (i) Profits up 31%-8% ahead of expectations; (ii) Margins up…
Near-term negative catalysts: Our conversations with company managements and channel financiers indicate that there is a build-up of inventories in…
SAIL’s Q4 adjusted PAT of R15bn was 26% lower year-on-year and 4% below our estimate. Ebitda margin was 19% in…
Coal India has signed a memorandum of understanding with the ministry of coal for key performance areas for FY12.
Revenues at Voltas grew by 5%YoY, 4% below expectations. Margins declined by 152 bps to 7.3% against CIRA expectations of…
Biocon reported Q3 numbers higher than our expectations, almost entirely driven by higher licensing income during the quarter.
A favourable court ruling has once again paved the way for Sun to launch generic Eloxatin at risk in the…
The US approval for Ranbaxy?s generic version of Aricept may boost Ranbaxy shares.
We increase our target price Rs 164 to reflect roll?forward of DCF and the fact we now value Dahej port…
Brokerage to bank? ?Edelweiss Capital?s revenue bias has tilted more towards interest income over recent quarters as the management focuses…
After our downgrade to Sell (3M) in January 2010 at Rs 223, the Punj Lloyd stock has corrected about 50%.
The fundamental problem with the country?s macro indicators has been…
